• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.

作者信息

Shafer Robert W, Nguyen Dong Phuong, Fessel W Jeffrey

机构信息

Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.

出版信息

MedGenMed. 2006 Aug 7;8(3):32.

PMID:17406166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1781271/
Abstract
摘要

相似文献

1
Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.斯坦福大学医学中心的病例档案：对未经治疗的HIV患者进行耐药性检测——了解需关注的要点并选择合适的治疗方法。
MedGenMed. 2006 Aug 7;8(3):32.
2
Interpretation of resistance assay results.耐药性检测结果的解读。
Antivir Ther. 2001;6 Suppl 2:1-9.
3
HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.人类免疫缺陷病毒1型耐药性检测。国际艾滋病防治协会会议，2001年7月18 - 19日，芝加哥
IAPAC Mon. 2001 Aug;7(8):235-7.
4
Clinical utility of resistance testing.耐药性检测的临床应用
J HIV Ther. 2002 Nov;7(4):75-9.
5
Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois.第八届逆转录病毒与机会性感染会议精选主题。2001年2月4日至8日。伊利诺伊州芝加哥。
HIV Clin Trials. 2001 May-Jun;2(3):219-26. doi: 10.1310/M79M-C5Q5-9ATV-1AM5.
6
[Resistance screening].[耐药性筛查]
MMW Fortschr Med. 2009 Apr 30;151(18):72, 74-5.
7
Limitations and uncertainties of resistance testing: a review of "negative" trials. IAPAC sessions 2001, July 18-19, 2001 - Chicago.耐药性检测的局限性与不确定性：对“阴性”试验的综述。2001年国际抗寄生虫药物大会会议，2001年7月18 - 19日，芝加哥
IAPAC Mon. 2001 Aug;7(8):237-41.
8
Antiretroviral resistance.抗逆转录病毒耐药性
J HIV Ther. 2006 Dec;11(4):72-3.
9
Current insights into reverse transcriptase inhibitor-associated resistance.逆转录酶抑制剂相关耐药性的当前见解。
Antivir Ther. 2001;6 Suppl 2:11-9.
10
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.在接受含非核苷类逆转录酶抑制剂（NNRTI）的初始三联疗法的患者中，NNRTI敏感性的适度降低不会影响病毒学结果。
Antivir Ther. 2003 Oct;8(5):395-402.

引用本文的文献

1
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.大型社区抗逆转录病毒治疗项目中初治患者及首次病毒学失败后的HIV-1 C亚型耐药基因型
Antivir Ther. 2009;14(4):523-31.

本文引用的文献

1
Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet.斯坦福大学医学中心的病例档案：HIV-1感染的初次表现——公共健康与个人健康的交汇点。
MedGenMed. 2006 Jan 26;8(1):24.
2
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.基线和治疗相关因素对HIV-1阳性受试者开始抗逆转录病毒治疗后免疫恢复的影响：ACTG 384研究结果
J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34. doi: 10.1097/01.qai.0000226789.51992.3f.
3
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.抑制性抗逆转录病毒治疗期间CD4 + T细胞恢复的决定因素：免疫激活、T细胞成熟标志物与细胞内HIV-1 DNA的关联
J Infect Dis. 2006 Jul 1;194(1):29-37. doi: 10.1086/504718. Epub 2006 May 18.
4
Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing.原发性HIV耐药性及耐药性检测指导下的一线抗逆转录病毒疗法的疗效
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):573-81. doi: 10.1097/01.qai.0000214805.52723.c1.
5
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.初治HIV感染患者是否应进行耐药性检测？一项成本效益分析。
Clin Infect Dis. 2005 Nov 1;41(9):1316-23. doi: 10.1086/496984. Epub 2005 Sep 23.
6
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.接受高效抗逆转录病毒治疗的1型HIV感染者中CD4 T细胞恢复至<500个细胞/微升的特征、决定因素及临床相关性
Clin Infect Dis. 2005 Aug 1;41(3):361-72. doi: 10.1086/431484. Epub 2005 Jun 24.
7
Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.北美和欧洲原发性HIV耐药性的流行病学现状
Antivir Ther. 2004 Oct;9(5):695-702.
8
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.影响接受长期高效抗逆转录病毒治疗的HIV阳性患者CD4细胞计数增加的因素。
J Infect Dis. 2004 Nov 15;190(10):1860-8. doi: 10.1086/425075. Epub 2004 Oct 8.
9
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.215例开始接受含胸苷类似物的首次高效抗逆转录病毒治疗的HIV-1逆转者的治疗失败风险。
AIDS. 2004 Jan 23;18(2):227-35. doi: 10.1097/00002030-200401230-00012.
10
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.用于HIV-1感染初始治疗的序贯三联药物方案比较。
N Engl J Med. 2003 Dec 11;349(24):2293-303. doi: 10.1056/NEJMoa030264.